Julie Zhen Qin Wu

Array ( [id] => 17982632 [patent_doc_number] => 20220348668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => ANTI-CD123 ANTIBODIES, ANTI-CD123 CHIMERIC ANTIGEN RECEPTORS AND ANTI-CD123 CHIMERIC ANTIGEN RECEPTORS T CELLS [patent_app_type] => utility [patent_app_number] => 17/621504 [patent_app_country] => US [patent_app_date] => 2020-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 798 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17621504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16620031 [patent_doc_number] => 20210038684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => Compositions and Methods for Cancer Immunotherapy [patent_app_type] => utility [patent_app_number] => 16/898008 [patent_app_country] => US [patent_app_date] => 2020-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29510 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16898008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17929828 [patent_doc_number] => 20220324953 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-13 [patent_title] => ANTI-CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/615801 [patent_app_country] => US [patent_app_date] => 2020-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 242 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17615801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17777913 [patent_doc_number] => 20220244263 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS [patent_app_type] => utility [patent_app_number] => 17/613881 [patent_app_country] => US [patent_app_date] => 2020-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 100740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17613881 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17828543 [patent_doc_number] => 20220265847 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => METHODS AND COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER [patent_app_type] => utility [patent_app_number] => 17/611019 [patent_app_country] => US [patent_app_date] => 2020-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22939 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -71 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17611019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17733290 [patent_doc_number] => 20220218749 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => CAR T-CELLS TARGETING BCMA AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/607192 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14186 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607192 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17704623 [patent_doc_number] => 20220204629 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => ANTI-GALECTIN-9 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/598215 [patent_app_country] => US [patent_app_date] => 2020-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17598215 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595376 [patent_doc_number] => 20220144949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => CONDITIONALLY ACTIVATED BINDING PROTEINS CONTAINING Fc REGIONS AND MOIETIES TARGETING TUMOR ANTIGENS [patent_app_type] => utility [patent_app_number] => 17/435931 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36693 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -69 [patent_words_short_claim] => 181 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17435931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17480689 [patent_doc_number] => 20220088193 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => Anti-CD55 Antibodies and Related Compositions and Methods [patent_app_type] => utility [patent_app_number] => 17/431107 [patent_app_country] => US [patent_app_date] => 2020-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20065 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -102 [patent_words_short_claim] => 171 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17431107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443822 [patent_doc_number] => 20220064327 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => FIXAXFX BISPECIFIC ANTIBODY WITH COMMON LIGHT CHAIN [patent_app_type] => utility [patent_app_number] => 17/311595 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62916 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15882875 [patent_doc_number] => 10647769 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2020-05-12 [patent_title] => Antibody for treating autoimmune diseases [patent_app_type] => utility [patent_app_number] => 16/677506 [patent_app_country] => US [patent_app_date] => 2019-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 103 [patent_no_of_words] => 42016 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16677506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15294181 [patent_doc_number] => 20190390226 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-26 [patent_title] => NUCLEIC ACID-GUIDED NUCLEASES [patent_app_type] => utility [patent_app_number] => 16/548631 [patent_app_country] => US [patent_app_date] => 2019-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38423 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16548631 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17111840 [patent_doc_number] => 20210292437 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-23 [patent_title] => CHIMERIC QUIESCIN SULFHYDRYL OXIDASE (QSOX1) ANTIBODIES AND USES OF SAME [patent_app_type] => utility [patent_app_number] => 17/267049 [patent_app_country] => US [patent_app_date] => 2019-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24036 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17267049 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15020811 [patent_doc_number] => 20190321410 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-24 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC ANTIGENS [patent_app_type] => utility [patent_app_number] => 16/451934 [patent_app_country] => US [patent_app_date] => 2019-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26543 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16451934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15694455 [patent_doc_number] => 10603389 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-03-31 [patent_title] => Anti-cMet antibody drug conjugates and methods for their use [patent_app_type] => utility [patent_app_number] => 16/424324 [patent_app_country] => US [patent_app_date] => 2019-05-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 38 [patent_no_of_words] => 53990 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16424324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15524877 [patent_doc_number] => 20200054744 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => PSMA-RELATED THERAPIES [patent_app_type] => utility [patent_app_number] => 16/397730 [patent_app_country] => US [patent_app_date] => 2019-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16397730 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17830154 [patent_doc_number] => 20220267458 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => MINIATURIZED ANTIBODY OF ANTI-GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR), AND POLYMER AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/771777 [patent_app_country] => US [patent_app_date] => 2019-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16771777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14864553 [patent_doc_number] => 20190282518 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => EPINEPHRINE SPRAY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 16/355484 [patent_app_country] => US [patent_app_date] => 2019-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 85017 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16355484 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14338673 [patent_doc_number] => 20190151309 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => COMBINATION OF BREXPIPRAZOLE AND NALMEFENE AND USE THEREOF FOR TREATING SUBSTANCE-RELATED DISORDERS [patent_app_type] => utility [patent_app_number] => 16/250548 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16250548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14213783 [patent_doc_number] => 20190119276 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => 3-(1H-BENZO[D]IMIDAZOL-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINE AND THERAPEUTIC USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/224160 [patent_app_country] => US [patent_app_date] => 2018-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 662 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16224160 [rel_patent_id] =>[rel_patent_doc_number] =>)